# AVEO Oncology (United States)

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/aveo-oncology-united-states/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 48.8 |
| Citations | 120,536 |
| City | Cambridge |
| Country | US |
| Description | AVEO Oncology (United States) is a research organisation in Cambridge, US. OpenAlex records 1,134 works and 120,536 citations for it. 533 researchers list it as their most recent affiliation. |
| Homepage | https://www.aveooncology.com/ |
| OpenAlex ID | https://openalex.org/I4210085864 |
| Region | Massachusetts |
| Researchers | 533 |
| ROR ID | https://ror.org/000mrza07 |
| Type | company |
| Works | 1,134 |

## University papers

- [Food, nutrition, physical activity, and the prevention of cancer: a global perspective](https://scholariq.org/papers/food-nutrition-physical-activity-and-the-prevention-of-cancer-a-global/)
- [Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer](https://scholariq.org/papers/durvalumab-after-chemoradiotherapy-in-stage-iii-non-small-cell-lung-cancer/)
- [Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC](https://scholariq.org/papers/overall-survival-with-durvalumab-after-chemoradiotherapy-in-stage-iii-nsclc/)
- [Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study](https://scholariq.org/papers/durvalumab-as-third-line-or-later-treatment-for-advanced-non-small-cell-lung/)
- [Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC](https://scholariq.org/papers/three-year-overall-survival-with-durvalumab-after-chemoradiotherapy-in-stage-iii/)

## University top topics

Showing 8 of 25.

- [Multiple Myeloma Research and Treatments](https://scholariq.org/topics/multiple-myeloma-research-and-treatments/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)
- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Asthma and respiratory diseases](https://scholariq.org/topics/asthma-and-respiratory-diseases/)
- [Chronic Lymphocytic Leukemia Research](https://scholariq.org/topics/chronic-lymphocytic-leukemia-research/)
- [Lysosomal Storage Disorders Research](https://scholariq.org/topics/lysosomal-storage-disorders-research/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.